You can Subscribe to IPO Boutique’s Secondary Only Service by clicking here: This past week 15 secondary offerings came to market and IPO Boutique placed BUY ratings on 6 of them. This week, $2.25bn was raised by companies in the secondary market. The average gain of BUY rated offerings this week at first trade[…]
IPO Weekly Recap: Mixed biotech debuts, Dova Pharmaceuticals flies but Mersana Therapeutics tanks
This past week eight IPOs debuted marking one of the busiest IPO weeks of 2017 thus far. Biotech deals had a very mixed week and other new issues showed price sensitivity in an extremely busy week for the IPO market. The best deal this week, Dova Pharmaceuticals (Nasdaq: DOVA), upsized its offering 10% and[…]
IPO Pipeline Update: New Filings & Updated Terms (Week ending 6.30.17)
IPO Boutique keeps apprised of the active pipeline. Currently there are 56 active IPOs in the pipeline as of June 30, 2016. No SPACs or Unit Offerings are included. TERMS ADDED Company: RBB Bancorp Symbol: TBD Description: RBB Bancorp adopted a strategic plan focused on providing commercial banking services to first generation immigrants, initially concentrating[…]
Secondaries Announced 6.29.17
Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or[…]
Akcea Therapeutics, Inc. IPO Preview
Company: Akcea Therapeutics, Inc. Symbol: AKCA Description: They are a late-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Shares: 9.62 million Price Range: $12.00-$14.00 Trade Date: 6/30 Underwriter(s): Cowen and Company, Stifel, Wells Fargo Securities Co-Manager: BMO Capital Markets Link to S-1/A Prospectus[…]
Secondaries Announced 6.28.17
Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or[…]
Aileron Therapeutics, Inc. IPO Preview
Company: Aileron Therapeutics, Inc. Symbol: ALRN Description: They are a clinical-stage biopharmaceutical company that is focused on developing and commercializing a novel class of therapeutics called stapled peptides. Shares: 3.75 million Price Range: $15.00-$17.00 Trade Date: 6/29 Underwriter(s): BofA Merrill Lynch, Jefferies Co-Manager: William Blair, Canaccord Genuity Link to S-1/A Prospectus Investor Access: This deal[…]
Byline Bancorp, Inc. IPO Preview
Company: Byline Bancorp, Inc. Symbol: BY Description: They are a bank holding company headquartered in Chicago, Illinois and conduct all their business activities through their subsidiary, Byline Bank, a full service commercial bank. Shares: 5.7 million Price Range: $19.00-$21.00 Trade Date: 6/29 Underwriter(s): BofA Merrill Lynch, Keefe Bruyette & Woods Co-Manager: Piper Jaffray, Sandler O’Neill[…]
Tintri, Inc. IPO Preview
Company: Tintri, Inc. Symbol: TNTR Description Their highly-differentiated and extensible enterprise cloud platform combines cloud management software, web services and a range of all-flash storage systems. Shares: 8.7 million Price Range: $10.50-$12.50 Trade Date: 6/29 Underwriter(s): Morgan Stanley, BofA Merrill Lynch, Pacific Crest Securities Co-Manager: Needham & Company, Piper Jaffray, Raymond James, William Blair Link[…]
Secondaries Announced 6.27.17
Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis. For example, this is not to be interpreted as a Buy recommendation in the traditional sense of adding to your stock portfolio; this is a short term (usually one day or[…]
Dova Pharmaceuticals, Inc. IPO Preview
Company: Dova Pharmaceuticals, Inc. Symbol: DOVA Description: They are a pharmaceutical company focused on acquiring, developing and commercializing drug candidates for diseases that are treated by specialist physicians, with an initial focus on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Shares: 4.1 million Price Range: $15.00-$17.00 Trade Date: 6/29 Underwriter(s): J.P.[…]
Blue Apron Holdings, Inc. IPO Preview
Company: Blue Apron Holdings, Inc. Symbol: APRN Description: Blue Apron was founded in 2012 premised on a simple desire our founders wanted to cook at home with their families, but they found grocery shopping and menu planning burdensome, time consuming, and expensive. Shares: 30 million Price Range: $15.00-$17.00 Trade Date: 6/29 Underwriter(s): Goldman Sachs &[…]
Mersana Therapeutics, Inc. IPO Preview
Company: Mersana Therapeutics, Inc. Symbol: MRSN Description They are a clinical stage biopharmaceutical company focused on developing antibody drug conjugates, or ADCs, that offer a clinically meaningful benefit for cancer patients with significant unmet need. Shares: 5 million Price Range: $14.00-$16.00 Trade Date: 6/28 Underwriter(s): J.P. Morgan, Cowen and Company, Leerink Partners Co-Manager: Wedbush PacGrow[…]
Esquire Financial Holdings, Inc. IPO Preview
Company: Esquire Financial Holdings, Inc. Symbol: ESQ Description: They are a bank holding company headquartered in Jericho, New York and registered under the Bank Holding Company Act of 1956, as amended (the “BHC Act”). Shares: 2.5 million Price Range: $14.00-$16.00 Trade Date: 6/27 Underwriter(s): Sandler O’ Neill + Partners Link to S-1/A Prospectus Investor Access:[…]
IPO Weekly Recap: 37% upsize does not stop Altice momentum
Four IPOs came to market including a strong debut from the second largest cash raise to debut in 2017. Altice USA (NYSE: ATUS) upsized its offering 37% and raised $1.91bn with a slightly above mid-range $30.00 pricing. ‘ATUS’ opened with a first trade of $31.60, or 5.3% above the offering price, and rallied in its[…]
Secondary Offering Performance Review – Week Ending 6.23.17
This past week 10 secondary offerings came to market and IPO Boutique placed BUY ratings on 6 of them. This week, $1.33bn was raised by companies in the secondary market. You can Subscribe to IPO Boutique’s Secondary Only Service by clicking here: The average gain of BUY rated offerings this week at first trade was[…]
Healthcare in spotlight for busy final week of June
SIGN UP FOR IPO BOUTIQUE’S FREE NEWSLETTER There are ten IPOs on the schedule for this week including five healthcare offerings. Below is the IPO schedule for the upcoming week: Tuesday – 6/27 Avenue Therapeutics (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl,[…]
IPO Pipeline Update: New Filings & Updated Terms (Week ending 6.23.17)
New Filings & Updated Terms (Week ending 6.23.17) IPO Boutique keeps apprised of the active pipeline. Currently there are 56 active IPOs in the pipeline as of June 2, 2016. No SPACs or Unit Offerings are included. NEW FILINGS Company: Vencore Holding Corp. Symbol: VNCR Description: Vencore is a leading provider of mission-critical, innovation-driven services[…]
Secondaries Announced 6.22.17
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]
Secondaries Announced 6.21.17
IPO BOUTIQUE CLIENTS and IPO BOUTIQUE SECONDARY ALERTS CLIENTS received ALL this information to their inbox on a REAL TIME basis. If having real-time alerts for secondary offerings would be an advantage to you, inquire about a subscription today! Our Buy, Neutral or Avoid ratings of the Secondaries below are intended as a recommendation for those who buy Secondaries on a regular basis.[…]